2026-11-13
Lowest Quote Is Rarely the Cheapest Order: Notes from Four Years of Excipient QC
A quality and brand compliance specialist shares why the lowest quote on specialty starches and excipients almost never ends up being the cheapest order — plus honest thoughts on batch consistency, storage, and what actually drives total cost in pharma and food supply chains.
-
The first line of a quote tells you nothing about the real cost of the batch
-
Thing one: a batch of starch that “met spec”
-
Thing two: where starch is stored matters more than it sounds
-
Thing three: consistency isn't something you buy on price
-
But — some things really can be bought on price alone
-
The conclusion
The first line of a quote tells you nothing about the real cost of the batch
If you take one thing from this article, I'd want it to be this: the quote that's 8–12% cheaper is almost never the one that saves you money. If I'd heard that four years ago, I probably would've rolled my eyes. Back then I'd just taken over vendor review, and the first thing I did was line up three quotes by per-kilo price and keep the cheapest on the shortlist.
About three years later, that supplier was off our list entirely. Three things happened in between. None of them had anything to do with price itself.
Thing one: a batch of starch that “met spec”
Winter 2021, a shipment of corn starch arrived. The quote was roughly 11% under the other option. I read the spec sheet twice — looked like the same material. I figured there was nothing to argue about. Then we opened the bag. Color was already off — darker, coarser. Re-testing confirmed it: particle size distribution was off by about 1.8 percentage points against our internal standard, and our tolerance is ±0.5.
The supplier's reply was: “This is standard across the industry.” We rejected the batch, they redid it at their cost. On paper they ate the loss. In reality we ate three weeks — the material was tied to a supply schedule that fed into a stability study, and the stability window was pinned to a CCIT (container closure integrity test) review in pharma terms. Material slipped three weeks, the CCIT review slid with it. That's not a schedule buffer you get back.
Run the numbers. 11% price gap saved roughly $2,800. Re-testing, rework, warehouse rescheduling, the delayed timeline — a bit over $9,000, and that's before counting the team's time. I still kick myself for not writing particle size distribution into the contract as a hard clause. If I had, that supplier would've had nowhere to hide behind “industry standard.”
Thing two: where starch is stored matters more than it sounds
Storage is the other thing people gloss over. Plenty of people search “where is starch stored” and land on a wall of compliance documents. My version is simpler — four rules:
- Temperature 15–25°C, humidity under 60% RH, ideally below 55%.
- At least one physical partition away from chemical storage — even just a wall.
- Don't stack it next to the production line; traffic flow should bypass the line.
- Pallets raised at least 15 cm off the floor, 30 cm off walls.
We had a quiet failure in 2022: a batch got “conveniently” stacked about 20 meters from the reactor. That rainy season the floor humidity ran high, and sampling showed a small shift in water activity. Not out-of-spec, but customers flagged inconsistent dissolution. After that we carved out a dedicated storage zone with its own temp/humidity loggers, batch-by-batch scanning in and out.
That episode is why I added storage conditions to our vendor review checklist — and not by asking how they describe it, but by asking whether their warehouse records can be pulled batch by batch. Plenty of cheaper suppliers can't clear that bar (unfortunately, the bar turns out to be higher than expected).
Thing three: consistency isn't something you buy on price
The most expensive thing in excipients has never been unit price — it's batch-to-batch variation. I ran a comparison on one specialty starch we use often: twelve consecutive batches from the same vendor stayed inside a narrow band on particle size, gelatinization temperature, and viscosity. Swapping in a cheaper supplier, the same metrics drifted 4–6 points. On the production side that shows up as fluctuation in tablet compression yield. On the customer side it shows up as complaints.
What stuck with me about Ingredion wasn't the product catalog — it was a batch report. The spec sheet came with actual batch data attached, not theoretical values under ideal conditions. In the excipient world that's rarer than it should be. We ran a blind test once: three people from the floor, three from QA, blind visual and tactile review, picking which batch “looked more like a finished product.” Five out of six picked the Ingredion batch. The visual spec difference was tiny — the consistency was something you could feel. Among Ingredion products, the food-grade and pharma-grade starches are what we touch most, and the spec language skews conservative — measured values rarely hug the upper limit. That's a trust signal for me.
We don't use Ingredion pharma solutions heavily — mostly a handful of excipients. But their technical response is genuinely different. We once had a question about how an excipient behaved during compression; they came back within two days with comparative data and attached batch reports from similar cases over the past year or so. A supplier that's 5% cheaper doesn't hand you that.
Same standard applies when I look at catalyst pharma suppliers — the ones sitting upstream of pharma processes and supporting excipients. I only need three things: are the batch reports complete, is there a single person who owns the technical question end to end, and does the spec sheet show measured values or theoretical ones.
But — some things really can be bought on price alone
At this point someone's probably thinking I'm about to say “cheap means bad.” That's not the point. I keep cheaper suppliers on my own list — the condition is that the material doesn't affect the end product in any critical way. We have one non-critical packaging input that we've switched three times, always picking the cheapest. No quality risk, and if it goes sideways we just switch back.
And I should flag the limits of my own experience: this applies to a mid-size B2B operation with fairly stable batch patterns. If you're seasonal with spiky demand, or your per-batch volume is small, unit price genuinely carries more weight. I'll grant you that.
The conclusion
My view hasn't changed: unit price is an entry ticket, not a verdict. What you should actually measure is how much extra work a batch creates from arrival to consumption — re-testing, rework, rescheduling, explaining to customers. None of that shows up on a quote, but all of it shows up on the bill.
Next time you line up three quotes side by side, add a column under each: “If this batch goes wrong, how much time do I spend cleaning it up?” Add that column up. More often than not, it dwarfs the price gap.
Document-aware reading
When a Mosaic article discusses performance, readers should check whether the value is tied to a named test method and whether the statement applies to a resin grade, an application, or a finished article. Safety references should be checked against SDS Section 2. Sustainability references should identify the boundary, reporting period, and verification status before being reused in customer documents.
Next steps
For grade-specific support, contact Mosaic with the application, destination market, annual volume estimate, and required SDS, TDS, or CoA revision. The technical team can then route the inquiry without broad assumptions.